Meissa to bring synthetic RSV vaccine to clinic with $30M series A

With preclinical data in hand and manufacturing capabilities established, Meissa raised $30 million in a series A from new investor Morningside Ventures to bring its synthetic biology-based universal RSV vaccine to the clinic next quarter.

Meissa Vaccines Inc. CEO Martin Moore told BioCentury the company expects to fund at least three clinical trials of its respiratory syncytial virus vaccine with the financing, which will give the company a runway of three to four years. ...